bf/NASDAQ:CADL_icon.jpeg

NASDAQ:CADL

Candel Therapeutics

  • Stock

4.89

−0.41%

−1.32

USD last updated 11/08 02:03:55

Last Close

6.21

11/08 20:01

Market Cap

178.24M

Beta: -

Volume Today

874.73K

Avg: 28.77K

PE Ratio

−2.46

PFCF: −1.09

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as wel...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -0.8-0.6-0.4-0.20.20.42020-03-302020-12-302021-12-312022-12-312024-05-09

    Revenue (Estimate*)

    5K10K15K20K25K30K35K2020-03-302020-12-302021-12-312022-12-312024-05-09

    *Estimate based on analyst consensus